Taysha Gene Therapies (TSHA) Equity Average: 2022-2025
Historic Equity Average for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $233.9 million.
- Taysha Gene Therapies' Equity Average rose 136.62% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 136.62%. This contributed to the annual value of $73.2 million for FY2024, which is 93.00% up from last year.
- Taysha Gene Therapies' Equity Average amounted to $233.9 million in Q3 2025, which was up 53.96% from $151.9 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Equity Average peaked at $233.9 million during Q3 2025, and registered a low of -$43.1 million during Q3 2023.
- Over the past 3 years, Taysha Gene Therapies' median Equity Average value was $64.4 million (recorded in 2024), while the average stood at $64.6 million.
- In the last 5 years, Taysha Gene Therapies' Equity Average tumbled by 299.56% in 2023 and then spiked by 1,019.97% in 2024.
- Over the past 4 years, Taysha Gene Therapies' Equity Average (Quarterly) stood at $5.8 million in 2022, then spiked by 121.62% to $12.9 million in 2023, then surged by 520.85% to $80.2 million in 2024, then spiked by 136.62% to $233.9 million in 2025.
- Its last three reported values are $233.9 million in Q3 2025, $151.9 million for Q2 2025, and $63.3 million during Q1 2025.